Joseph J. Stephenson

Author

Dana-Farber Cancer Institute

Also Known As

J. J. STEPHENSON, J. J. Stephenson, Joseph J. Stephenson

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

Dana-Farber Cancer Institute Memorial Sloan Kettering Cancer Center University of Washington Cornell University

About

Joseph J. Stephenson is an author at Dana-Farber Cancer Institute specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	761
2	Pharmacology	3	3	133
3	Cancer Therapeutics	3	3	656
4	Health Sciences	1	1	628
5	Pathology	1	1	628

Joseph J. Stephenson

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers Daniel D. Von Hoff, Joseph J. Stephenson, Peter J. Rosen, Journal of Clinical Oncology Cancer ManagementOligonucleotide MicroarrayPathologyTumor BiologyPfs Ratio	2010	628
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced <i>BRAF</i>-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134 Michael B. Atkins, Sandra J. Lee, Bartosz Chmielowski, Journal of Clinical Oncology	2022	402
A First in Human Phase 1 Study of CG0070, a GM-CSF Expressing Oncolytic Adenovirus, for the Treatment of Nonmuscle Invasive Bladder Cancer James M. Burke, Donald L. Lamm, Maxwell V. Meng, The Journal of Urology	2012	227
Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors Antoinette R. Tan, Darlene Gibbon, Mark N. Stein, Cancer Chemotherapy and Pharmacology OncologySolid TumorsPharmacologyPharmacotherapyAnti-cancer Agent	2013	105
Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer Bruce Montgomery, Mario A. Eisenberger, Matthew B. Rettig, Clinical Cancer Research	2015	79
Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial Azra Raza, Joseph G. Jurcic, Gail J. Roboz, Leukemia & lymphoma/Leukemia and lymphoma	2009	60
Serial Bone Scanning: The Assessment of Treatment Response in Carcinoma of the Prostate J. M. Fitzpatrick, A. R. Constable, Thomas Sherwood, British Journal of Urology	1978	42
Phase I multicenter trial of perifosine in combination with sorafenib for patients with advanced cancers including renal cell carcinoma Marshall T. Schreeder, Robert A. Figlin, Joseph J. Stephenson, Journal of Clinical Oncology UrologyChemoprevention StrategyGenitourinary CancerAdvanced CancersMedicine	2008	15
Pharmacokinetic (PK) analysis of a phase I study of continuous oral treatment with the angiokinase inhibitor BIBF 1120, in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer (NSCLC) D. Ross Camidge, Paul Conkling, Joseph J. Stephenson, Journal of Clinical Oncology Continuous Oral TreatmentOncologyBibf 1120Metronomic TherapyPharmacology	2008	13

Page 1